According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:
1. Bristol Myers Squibb Co (NYSE:BMY)
The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: B.
Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 52, which is 17 points higher than the general drug manufacturer industry average of 35.
BMY passed 19 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 36.96% over the past year, underperforming other general drug manufacturer stocks by -4 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $64.83, an upside of 3.77% from Bristol Myers Squibb Co's current stock price of $62.48.
Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 46.15% have issued a Strong Buy rating, 0% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.
2. Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year.
Learn more.
The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: C, and AI: C.
Biogen (NASDAQ:BIIB) has a Due Diligence Score of 39, which is 4 points higher than the general drug manufacturer industry average of 35.
BIIB passed 12 out of 33 due diligence checks and has average fundamentals. Biogen has seen its stock return 69.52% over the past year, overperforming other general drug manufacturer stocks by 28 percentage points.
Biogen has an average 1 year
price target of $260.86, an upside of 2.85% from Biogen's current stock price of $253.62.
Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 22 analysts covering Biogen, 40.91% have issued a Strong Buy rating, 31.82% have issued a Buy, 22.73% have issued a hold, while 4.55% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Novartis Ag (NYSE:NVS)
Novartis Ag (NYSE:NVS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year.
Learn more.
The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.
Novartis Ag (NYSE:NVS) has a Due Diligence Score of 30, which is -5 points lower than the general drug manufacturer industry average of 35. Although this number is below the industry average, our proven quant model rates NVS as a "B".
NVS passed 10 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 31.14% over the past year, underperforming other general drug manufacturer stocks by -10 percentage points.
Novartis Ag has an average 1 year
price target of $136.00, a downside of -15.42% from Novartis Ag's current stock price of $160.79.
Novartis Ag stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Novartis Ag, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.
